NCT03331081

Brief Summary

The question is whether vesical training and TMAP can be used in isolation without treatment of overactive bladder syndrome? ALSO will be evaluated in urinary symptoms, a function of the MAP, a quality of life and a satisfaction of the women with the treatment offered.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
45

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2017

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 25, 2017

Completed
12 days until next milestone

First Posted

Study publicly available on registry

November 6, 2017

Completed
19 days until next milestone

Study Start

First participant enrolled

November 25, 2017

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2018

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 20, 2018

Completed
Last Updated

November 6, 2017

Status Verified

October 1, 2017

Enrollment Period

7 months

First QC Date

October 25, 2017

Last Update Submit

October 31, 2017

Conditions

Keywords

Overactive Bladder Syndrome

Outcome Measures

Primary Outcomes (1)

  • Evaluation of subjective cure

    We consider it "satisfied" when the patient does not want another treatment, and "dissatisfied" when the patient wants another treatment option.

    At the end of 3 months of supervised treatment

Secondary Outcomes (8)

  • BMI

    At the initial evaluation of the patient before starting the 3 months of treatment

  • Urinary symptoms

    At the initial evaluation of the patient before starting the 3 months of treatment

  • Pregnancies and deliveries

    At the initial evaluation of the patient before starting the 3 months of treatment

  • Pad test

    At the initial evaluation of the patient before starting the 3 months of treatment and the end of 3 months of supervised treatment

  • V8 questionnaire

    At the initial evaluation of the patient before starting the 3 months of treatment and the end of 3 months of supervised treatment

  • +3 more secondary outcomes

Study Arms (3)

Group Bladder Training

EXPERIMENTAL

Patients will receive verbal instructions on bladder function (filling and bladder emptying phases), pelvic floor musculature on bladder function; orientation on urinary positioning and habits (urinary frequency); and the definition and major risk factors responsible for urinary incontinence.

Other: Bladder Training

Group TMAP

ACTIVE COMPARATOR

In this group the patients will perform TMAP in isolation. The training protocol aims at the work of strength and muscular hypertrophy, with concentric-isometric muscular action and load of 100% of the maximum voluntary contraction.

Other: TMAP

Group Bladder Training + TMAP

ACTIVE COMPARATOR

In this group, the patients should perform the proposed exercises for the Bladder Training Group and the exercises proposed for the TMAP Group. The training protocol of this group will consist of exercises that have as objectives: to improve the control over the urgency and urge-incontinence; increase bladder capacity, and thus prolong the intervals between urinations; to restore confidence in bladder control; and improve MAP strength and hypertrophy.

Other: Bladder Training + TMAP

Interventions

The patient will participate in a class in which the physiotherapist will provide the following information: on the anatomy and function of the MAP, using figures; on bladder function; guidelines on the positioning and voiding habits and the definition and main risk factors responsible for urinary incontinence. The bladder training will consist of a program of time micturition to increase bladder capacity and the interval between urinations. Urge suppression strategies will be targeted, and include distraction, relaxation, breathing, and MAP contraction (quick flicks).

Group Bladder Training
TMAPOTHER

There will be 36 monthly series of home training (totaling at the end of the 3 months of treatment 108 series) performed 3x / week, 3x / day. The training protocol consists of three daily TMAP series. One series consists of 8 maximum voluntary contractions, with maintenance of the contraction of 6 to 10 seconds (type I muscle fibers), with twice the rest time between contractions, followed by three to five rapid contractions (muscle fibers type II ). The protocol will total 24 contractions of MAP per day performed, which will be divided in the morning (8 contractions), late (8 contractions) and night (8 contractions).

Group TMAP

Will perform the exercises of the bladder training group and the TMAP in an associated way.

Group Bladder Training + TMAP

Eligibility Criteria

Age18 Years - 80 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Women with IUU and / or IUM with a predominance of urinary urgency, capable of contracting MAPs adequately, and who agree to participate in the study, signing the Informed Consent Form.

You may not qualify if:

  • Women with a diagnosis of glaucoma, myasthenia gravis, urinary tract obstruction, neurological and chronic-degenerative diseases, decompensated diabetic patients and patients with complete denervation of the pelvic floor, pregnancy, abnormal genital bleeding, impairment of cognition, inability to fill in the diary voiding, genital dystopias beyond the vaginal introitus and urethral sphincter defect. Patients may not be in use or have used anticholinergics, tricyclic antidepressants or local hormone therapy within the six months prior to the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Funada S, Yoshioka T, Luo Y, Sato A, Akamatsu S, Watanabe N. Bladder training for treating overactive bladder in adults. Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD013571. doi: 10.1002/14651858.CD013571.pub2.

MeSH Terms

Interventions

4,4',5'-trimethylazapsoralen

Study Officials

  • Letícia Ferreira

    Federal University of São Paulo

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Letícia Ferreira

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

October 25, 2017

First Posted

November 6, 2017

Study Start

November 25, 2017

Primary Completion

June 30, 2018

Study Completion

December 20, 2018

Last Updated

November 6, 2017

Record last verified: 2017-10